Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : MQ710
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Hanne Capital
Deal Size : $15.0 million
Deal Type : Series B Financing
Imvaq Therapeutics Raises $15 Million in Series B Financing to Fund IND and Phase 1 Trials
Details : The funds will enable the company to catalyze the Phase 1 clinical development of its first therapeutic candidate MQ710, a novel 2nd-generation viral immunotherapy based on armed Modified Vaccinia Ankara (MVA), and to advance additional novel assets in i...
Brand Name : MQ710
Molecule Type : Large molecule
Upfront Cash : Undisclosed
September 28, 2020
Lead Product(s) : MQ710
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Hanne Capital
Deal Size : $15.0 million
Deal Type : Series B Financing
LOOKING FOR A SUPPLIER?